At Partners4Access, we believe in striking an equilibrium in the orphan drug, cell and gene therapy world. That means helping drive access to the most appropriate treatments for patients and physicians, a fair return on investment for manufacturers at an affordable proposition for payers.
As a global company, we don’t just provide access services, we partner with our clients to help them achieve their PR&MA goals. A large part of that involves us supporting the right strategic and investment decisions. If you want to increase your success in launching an orphan drug at the right price and access conditions, Partners4Access are the right team for you.
Wednesday, June 23 2021 | 4pm BST (UK) / 11am (EST)
Focus on the EU5!” The geographical scope we have become used to identifying market opportunities and preparing the ground for orphan drug launches. After all, these 5 countries (France, Germany, Italy, Spain and UK) represent approximately 80% of potential healthcare spend in rare diseases in Europe and are duly prioritised by pharma companies. Now we are hearing requests for a different geographical scope when pharma is planning launches for orphan drugs and ATMPs: “Focus on the EU4” or more recently, “Focus on the EU4”. So, what has happened to the UK?
This webinar will set out two opinions: the first for including the UK as a priority market when developing launch strategies for orphan drugs and ATMPs; the second against including the UK as a strategic priority.
Director Europe, Otsuka
VP Market Access and HEOR, Deciphera
Senior Director, Blue Chip Pharma
Senior Director, GW Pharmaceuticals
